Virbac reports strong revenue growth and record operating income in 2024, with positive outlook for 2025.

From GlobeNewswire: 2025-03-13 12:45:00

Virbac reports a strong revenue increase of 13.6% at constant exchange rates, with operating income at an all-time high of 16.6% of revenues in 2024. Sales growth for 2025 is expected to be between 4% and 6%, with operating income stable at around 16%, excluding acquisitions. Consolidated figures for December 31, 2024, show revenues of €1,397.4 million, up 12.1% from 2023, with strong growth in all regions. Current operating income before depreciation of assets rose to €231.8 million, reflecting growth in gross margin and operating expenses due to higher personnel costs. Net income for 2024 was €145.8 million, up by 20.4% from 2023. Net debt decreased to €168.5 million, mainly due to acquisitions. The outlook for 2025 includes revenue growth, stable operating income, and plans to increase R&D investments. A net dividend per share of €1.45 will be recommended for distribution for the 2024 fiscal year. Analysts’ meeting will be held on March 14, 2025, to discuss the financial results and outlook. Virbac continues its mission of advancing animal health globally.



Read more at GlobeNewswire: Virbac: 2024 Annual results